|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from financial institutions | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investments in time deposits | ||||||||||||||||||||
| Securities available-for-sale | ||||||||||||||||||||
| Equity securities | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans, net of allowance for credit losses of $38,849 and $36,170 | ||||||||||||||||||||
| Loans, net of allowance for credit losses of $41,713 and $42,020 | ||||||||||||||||||||
| Other securities | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Swap assets | ||||||||||||||||||||
| Deferred taxes | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term Federal Home Loan Bank advances | ||||||||||||||||||||
| Long-term Federal Home Loan Bank advances | ||||||||||||||||||||
| Securities sold under agreement to repurchase | ||||||||||||||||||||
| Subordinated debentures | ||||||||||||||||||||
| Secured borrowings | ||||||||||||||||||||
| Other borrowings | ||||||||||||||||||||
| Swap liabilities | ||||||||||||||||||||
| Securities purchased payable | ||||||||||||||||||||
| Tax refunds in process | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Common shares, no par value, 40,000,000 shares authorized, 24,669,812 shares issued at June 30, 2026 and 24,607,544 shares issued at December 31, 2025, including Treasury shares | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury shares, 3,875,574 common shares at June 30, 2026 and 3,861,070 common shares at December 31, 2025, at cost | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
